Design, synthesis and biological evaluation of 2,4‐diamino‐6‐methyl‐5‐substitutedpyrrolo[2,3‐d]pyrimidines as dihydrofolate reductase inhibitors
暂无分享,去创建一个
[1] W. W. Barrow,et al. Identification and cloning of the Mycobacterium avium folA gene, required for dihydrofolate reductase activity. , 2006, FEMS microbiology letters.
[2] R. Miller,et al. Pneumocystis jirovecii infection , 2004, Thorax.
[3] Xin Lin,et al. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. , 2004, Journal of medicinal chemistry.
[4] M. Ihnat,et al. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. , 2003, Bioorganic & medicinal chemistry.
[5] I. Donkor,et al. Synthesis and DHFR inhibitory activity of a series of 6-substituted-2,4-diaminothieno[2,3-d]pyrimidines. , 2003, European journal of medicinal chemistry.
[6] F. Mavandadi,et al. Synthesis of classical and a nonclassical 2-amino-4-oxo-6-methyl-5-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of thymidylate synthase. , 1999, Journal of medicinal chemistry.
[7] V. Cody,et al. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines. , 1998, Journal of medicinal chemistry.
[8] S. Queener. New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. , 1995, Journal of medicinal chemistry.
[9] P K Bryant,et al. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 A resolution. , 1994, Structure.
[10] J. J. Heusner,et al. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. , 1993, Journal of medicinal chemistry.
[11] V. Georgiev. Opportunistic/nosocomial infections. Treatment and developmental therapeutics. Toxoplasmosis , 1993 .
[12] D. Roos. Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii. , 1993, The Journal of biological chemistry.
[13] H. Masur. Prevention and treatment of pneumocystis pneumonia. , 1992, The New England journal of medicine.
[14] J. Feinberg,et al. New developments in the treatment of Pneumocystis carinii pneumonia. , 1992, Chest.
[15] N Clumeck,et al. Treatment of Toxoplasmic Encephalitis in Patients with AIDS , 1992, Annals of Internal Medicine.
[16] M. Nettleman,et al. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. , 1991, JAMA.
[17] J. Smith,et al. Pneumocystis carinii, an opportunist in immunocompromised patients , 1991, Clinical Microbiology Reviews.
[18] M. Nassiri,et al. Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. , 1990, Journal of medicinal chemistry.
[19] D. Stover,et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. , 1990, Annals of internal medicine.
[20] J. Kovacs,et al. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. , 1989, The Journal of infectious diseases.
[21] A. Rosowsky,et al. 2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials. 3. Synthesis of 5,6-disubstituted derivatives and related tetracyclic analogs. , 1973, Journal of medicinal chemistry.
[22] F. Seela,et al. 7-Deazapurine Oligodeoxyribonucleotides: The effects of 7-deaza-8-methylguanine on dna structure and stability , 1998 .